Boey® (trenibotulinumtoxinE), developed by Allergan Aesthetics, received a positive opinion from the European Medicines Agency's CHMP for approval in 30 EU and EEA countries to temporarily improve moderate to severe glabellar lines in adults. Supported by two Phase 3 trials, Boey® showed rapid effects within 8 hours and lasted 2-3 weeks with a safety profile similar to placebo. If approved by the European Commission, Allergan plans to train healthcare professionals and launch the product commercially soon. This could be the first botulinum toxin serotype E treatment available for facial lines, addressing a significant psychological concern for many patients.
AbbVie presented new data at the 2026 ASCO Annual Meeting showcasing its oncology pipeline targeting solid tumors and blood cancers. Key findings include promising results from antibody-drug conjugates (ADCs) and T-cell engagers in cancers like metas...
More than 50 companies are actively developing over 55 new drugs for pulmonary arterial hypertension (PAH), a serious lung-related heart condition. These drugs are in various clinical trial stages, with several in late-stage development, aiming to im...
The iShares U.S. Pharmaceuticals ETF (IHE) has gained 38% over the past year despite threats from U.S. drug pricing policies like the 'most favored nation' order. The ETF benefits from dividends and strong drug pipelines, especially from major holdin...
The Vanguard Short-Term Corporate Bond Index ETF (VCSH) yields about 4.42%, significantly higher than typical 1-year CDs which offer around 1.5%-2.0%, with top CDs reaching 4.0%. While CDs provide FDIC insurance and guaranteed income, VCSH carries ri...
